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Yajuan Jiang,3 David W. O’Neill,3 Paul H. Krebsbach,2 Denis O. Rodgerson,3,{ and Russell S. Taichman1,{
The purpose of this study was to determine the lineage progression of human and murine very small embryonic-like
(HuVSEL or MuVSEL) cells in vitro and in vivo. In vitro, HuVSEL and MuVSEL cells differentiated into cells
of all three embryonic germ layers.HuVSELcells produced robustmineralized tissue of humanorigin comparedwith
controls in calvarial defects. Immunohistochemistry demonstrated that the HuVSEL cells gave rise to neurons,
adipocytes, chondrocytes, and osteoblasts within the calvarial defects. MuVSEL cells were also able to differentiate
into similar lineages. First round serial transplants of MuVSEL cells into irradiated osseous sites demonstrated
that*60% of the cells maintained their VSEL cell phenotype while other cells differentiated into multiple tissues at
3 months. Secondary transplants did not identify donor VSEL cells, suggesting limited self renewal but did dem-
onstrate VSEL cell derivatives in situ for up to 1 year. At no point were teratomas identified. These studies show that
VSEL cells produce multiple cellular structures in vivo and in vitro and lay the foundation for future cell-based
regenerative therapies for osseous, neural, and connective tissue disorders.
Key Points
HuVSEL and MuVSEL cells are capable of differentiating into multiple germline derivatives in vitro and in vivo.
MuVSEL cells have limited capacity for self-renewal and neither HuVSEL nor MuVSEL cells formed tumors in
immunodeficient animals.
Introduction
The regeneration of large and complex tissues result-ing from congenital or acquired deficiencies is a signif-
icant clinical challenge. Often the clinical needs surpass the
tissues available for autologous grafting. Just as challenging
is the frequent need for regenerating tissues to form tissues
that cross germline boundaries. To this end, numerous ap-
proaches have been undertaken utilizing embryonic stem
(ES) cells or induced pluripotent stem cells. Each of these
approaches has the advantage that large-scale production of
transplantable cells is possible, although at significant cost as
well as ethical and safety concerns [1–3].
Our group is interested in developing therapies for the
regeneration of craniofacial injuries or conditions, which
will require the development of multiple tissue components.
Previously, we demonstrated that a significant proportion of
the osseous regenerative capacity resides in a low-density
cellular fraction, which is resistant to agents that induce
apoptosis of cells actively undergoing DNA synthesis [4].
Furthermore, this population expresses the G-coupled re-
ceptor CXCR4 and therefore migrates rapidly in response to
stromal-derived factor-1 (SDF-1 or CXCL12) [5]. Fluores-
cence activated cell sorting (FACS) further identified very
small cells that do not express CD45 or other hematopoietic
lineage markers (Lin - ), and in mouse marrow expresses the
Sca-1 antigen [6,7]. These small, CXCL12-responsive,
Lin -Sca-1 +CD45 - cells had previously been described as
having embryonic-like features [6,7]. Therefore, the cells
were described as very small embryonic-like (VSEL) cells
[8,9]. Freshly isolated murine VSEL (MuVSEL) cells, when
implanted in vivo, generated mineralized structures with as
few as 500 cells, and when transplanted to a bone marrow
environment were able to differentiate into adipocytes [5].
VSEL cells represent a rare population in the bone mar-
row (less than 0.02% of nucleated cells) [10,11]. VSEL cells
have been identified in most tissues that have been examined
[12], including blood and other solid organs. MuVSEL cells
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range in size from 3 to 5 mm, while human VSEL (HuVSEL)
cells are slightly larger (4–10 mm) [6]. VSEL cells have
scant cytoplasm and, as the name suggests, have morpho-
logic characteristics indicative of an immature state of dif-
ferentiation, including dispersed chromatin [6]. In addition,
VSEL cells express genes that are expressed by ES cells,
including Oct4, nanog, and stage-specific embryonic antigen
SSEA-1 [13]. MuVSEL cells isolated from the marrow ex-
press markers characteristic for ES cells, epiblast stem cells,
or primordial germ cells [14]. Thus, VSEL cells may give
rise to derivatives of all three germ layers [14]. VSEL cells
may therefore be prime candidates for cells with the ca-
pacity to regenerate many different structures.
The purpose of this study was to determine the capacity
of HuVSEL and MuVSEL cells to differentiate into cells
that would participate in skeletal repair in vivo. We also
sought to determine the extent to which HuVSEL and
MuVSEL cells could generate cells of multiple lineages
within craniofacial wounds as well as in vitro. The results
demonstrate that both HuVSEL and MuVSEL cells are ca-
pable of multilineage cellular differentiation in vitro. In
vivo, multiple donor-derived tissue lineages, including en-
dothelial cells, neurons, adipocytes, chondrocytes, and os-
teoblasts, were observed to be derived from MuVSEL cells.
Similar tissues were generated from HuVSEL cells. At no
point, up to 3 months after transplantation or following three
rounds of serial transplantation with HuVSEL or MuVSEL
cells, were teratomas observed.
Materials and Methods
HuVSEL cell isolation
HuVSEL cells were isolated from peripheral blood
mononuclear cells of healthy Caucasian males following an
established mobilization and leukapheresis process. Apher-
esis products were collected under an IRB approved proto-
col at NeoStem’s laboratory in Cambridge, MA. Each donor
received daily injections (480 mg/day) of granulocyte colo-
ny-stimulating factor (G-CSF) (NEUPOGEN; Amgen,
Thousand Oaks, CA). Methods for apheresis, elutriation,
and FACS sorting of the CD34/CD133 + CD45 - VSEL cells
( < 10mm) are provided in the Supplementary Materials and
Methods, and Supplementary Fig. S1 (Supplementary Data
are available online at www.liebertpub.com/scd). FACS-
purified VSELs were typically *90% pure. FACS-purified
VSEL cells were frozen in the NeoStem Laboratory and
shipped overnight to the University of Michigan.
MuVSEL cell isolation
MuVSEL (Lin-Sca-1+CD45- cells) cells were isolated in
Ann Arbor from C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ
mice ( Jackson Laboratory, Bar Harbor, ME) using a BD
FACSAria (BD Biosciences, San Jose, CA) as reported
previously and see Supplementary Materials and Methods,
and Supplementary Fig. S2 [5]. Supplementary Fig. S3
demonstrates MuVSEL cells isolated by FACS and cytospin
and stained with an antibody to Oct4 and DAPI nuclear stain.
Induction of hematopoietic stress
C57BL/6 mice (Charles River Laboratories, Wilmington,
MA) were bled by jugular venipuncture under a protocol
approved by the University of Michigan Committee for the
Use and Care of Animals (UCUCA) at the University of
Michigan. The mice were anesthetized and *20%–30% of
the calculated blood volume (*0.55mL for a 20 g mouse)
was removed. Control mice were also anesthetized and
subjected to puncture without hemorrhage.
MuVSEL and HuVSEL cell culture
and differentiation in vitro
HuVSEL and MuVSEL cells were cultured and differ-
entiated as previously described. Briefly, C2C12 cells were
cultured in a growth medium (HG-DMEM; Invitrogen,
Grand Island, NY) containing 10% fetal bovine serum (In-
vitrogen) until almost 100% confluent and subsequently
treated with 10 mg/mL mitomycin-C (Sigma, St. Louis,
MO). HuVSEL and MuVSEL cells were plated at 300–500
cells per well (8-well chamber slide, Lab-Tek) for 1 week.
Later, the cells were switched to a differentiation medium
(Supplementary Materials and Methods).
Immunofluorescence microscopy
Pepsin treatment of paraffin sections was performed at 37C
for 15min before application of Image-iT FX signal enhancer
(Invitrogen, San Diego, CA) (30min) and fluorescence-
labeled primary antibodies. Poststaining fixation was per-
formed with 10% formalin (Sigma). Slides were mounted
with the ProLong Gold Antifade Reagent with DAPI (In-
vitrogen). Images were taken with the Olympus FV-500
confocal microscope. Antibodies used are presented in the
Supplementary Materials and Methods section.
Calvaria defect model
A 3-mm craniotomy defect was established in 5-week-old
female SCID mice (CB17-Prkdcscid/LCrlcoCrl) Charles
River Laboratories, Raleigh, NC) (n = 10–12) [15]. Scaf-
folds (Gelfoam; Pharmacia & Upjohn, Kalamazoo, MI)
loaded with either vehicle or HuVSEL cells were placed into
the defects. Mice were sacrificed at 3 months after the im-
plantation. As a positive control, bone marrow stromal cells
(BMSCs) from C57BL/6 mice ( Jackson Laboratory) were
transduced with AdCMVBMP-7 constructed by Cre-lox
recombination by Vector Core at the University of Michigan
[16,17]. Procedures were approved by the University
Committee on the Use and Care of Animals.
Microcomputed tomography
Calvaria were harvested and immediately fixed in 10%
neutral buffered formalin for 48 h. The bone specimens were
scanned at an 8.93 mm voxel resolution on an EVS Corp.,
microcomputed tomography (mCT) scanner (London, On-
tario, Canada), with a total of 667 slices per scan. GEMS
MicroView software was used to make a 3D reconstruction
from a set of scans. A fixed threshold (600) was used to
calculate the tissue mineral content.
Serial VSEL stem cell transplantation
Serial transplant studies were performed at intervals of
3 months by injecting green fluorescent protein (GFP)
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transgenic MuVSEL (small Lin -Sca-1 +CD45- ) cells iso-
lated from GFP transgenic murine bone marrow by multi-
parameter, live sterile cell sorting (BD FACSAria; BD
Biosciences)] [14]. Initially, 800 MuVSEL cells were in-
jected intra-tibially and suspended in PBS into 6- to 8-week-
old C57BL/6 male mice, which had been exposed to 600
cGray delivered as 300 cGray, 3 h apart. At 3 months, the
tibia was flushed and GFP + MuVSEL cells were recovered
by FACS and reinjected intra-tibially into irradiated sec-
ondary (Passage 1) recipient animals. As GFP + VSEL cells
(small (< 10 mm) Lin -Sca-1 +CD45 - cells) were found in
the Passage 1 transplanted animals, secondary (P2) and
tertiary (P3) studies were performed by serially transplanting
1,000 GFP+ (< 10mm) cells (See Supplementary Fig. S4).
Real-time polymerase chain reaction evaluations
For gene expression studies, real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) in conjunc-
tion with TaqMan probes reported to cross intron/exon
boundaries was used following reverse transcriptase using
primers presented in Table 1. Gene expression was nor-
malized to total murine b-actin or human GAPDH (ABI,
Grand Island, NY).
Statistical analysis
Statistical analysis was performed by ANOVA or un-
paired two-tailed Student’s t-test using the GraphPad Instat
(GraphPad Software, San Diego, CA) with significance at
P < 0.05. For the mCT analysis, a Kruskal–Wallis test and
Dunn’s multiple comparisons tests were utilized with the
level of significance set at P < 0.05.
Results
Our goal was first to determine if MuVSEL cells respond
to a physiologic wound by rapidly altering their expression
of gene sets associated with stem and mature cell markers.
Mice were phlebotomized and 2 days later, MuVSEL cells
were isolated. MuVSEL cells responded to the acute bleed by
decreasing their expression of stem cell markers (SSEA-1,
Bmi1, and Oct-4) while more mature cellular markers increased
(osteocalcin, collagen type 1, nestin, and PPAR-g) (Table 2).
In vitro differentiation of MuVSEL cells
Table 2 suggests that VSEL cells may differentiate into
mature phenotypes following physiologic stimuli. We
therefore determined if VSEL cells can generate cells of all
three germ layers in vitro. Alone, MuVSEL cells demon-
strated very limited proliferation and were unable to dif-
ferentiate (not shown). MuVSEL cells were therefore
isolated from GFP mice and placed on mitomycin-C-treated
C2C12 cells. After 2 weeks, the medium was switched to the
differentiation medium for up to two additional weeks be-
fore histological evaluation (Fig. 1A). Under osteoblastic
conditions, many C2C12 cells express Runx2 or osteocalcin,
markers indicative of osteoblast differentiation (Fig. 1B).
These C2C12 cells could be distinguished from the VSEL
cells by their larger nucleus and the lack of GFP expression.
At the same time, many of the GFP-expressing VSEL cells
strongly expressed Runx2 or osteocalcin (Fig. 1B). Under
endothelial conditions, significant expression of Factor VIII
and PECAM-1 (CD31) was observed for the GFP-expressing
cells (Fig. 1C). When MuVSEL cell/C2C12 cell cocultures
were induced toward neural differentiation, nestin and
neurofilament 200 expression was observed. In fact, many
of the cells exhibited a bipolar and multipolar morphology
with cell processes extending away from a central cell body
(Fig. 1D). Furthermore, when MuVSEL cells were placed
into a endodermal (pancreatic) differentiation medium, in-
sulin and C-peptide expression, was seen following cocul-
ture with C2C12 cells (Fig. 1E).
In vitro differentiation of HuVSEL cells
To determine if HuVSEL cells are also able to generate
cells from all three germ layers, HuVSEL cells were isolated
Table 1. Real-Time Polymerase Chain Reaction
Primers Used in Conjunction with Reverse





















Table 2. MuVSEL Gene Expression Change
48H After Acute Bleed Stress
Control Bleed
SSEA-1 1 0.38 – 0.03a
Bmi1 1 0.33 – 0.02a
Oct-4 1 0.15 – 0.04a
Osteocalcin 1 6.40 – 0.10a
Runx2 1 1.10 – 0.13
Collagen 1 1 8.11 – 0.10a
PPAR-g 1 4.61 – 0.68a
Gene expression measured by real-time PCR following reverse
transcriptase for VSEL cells recovered from the bone marrow of n= 3
animals following an acute bleed stress showed decrease in stem cell
markers, while mature cellular markers increased. Animals injected
with saline served as the control. Reverse transcriptase-polymerase
chain reaction (RT-PCR) was performed following reverse transcrip-
tion and the data are normalized against data generated from the
saline injected animals, which was set to 1. Data presented as
mean– std. deviation. Significance is indicated by a for P< 0.05.
MuVSEL, murine very small embryonic like.
HUVSEL AND MUVSEL CELLS GENERATE MULTIPLE TISSUES 691
from volunteers following G-CSF mobilization. Initial
studies were performed comparing the expression of se-
lected gene markers by G-CSF-mobilized HuVSEL cells
to CD45+ , CD34+ cells. Like the MuVSEL cells, HuVSEL
cells expressed Oct4 and Bmi1 and had lower levels of
expression of the mature marker osteocalcin compared
with controls (Table 3). Like MuVSEL cells, HuVSEL
cells alone had very limited capacity to proliferate when
placed into single cell or bulk cultures (10–100 cells/well)
(not shown). Therefore, cocultures to induce HuVSEL cell
differentiation using mitomycin-C-treated C2C12 cells were
used.
The ability of HuVSEL cells to express genes indicative
of cells of all three germ layers by QRT-PCR was deter-
mined (Fig. 2A). Following differentiation, the cocultures
were examined for expression of paired box gene 6 (PAX6),
which is required for endodermal pancreatic development
FIG.1. In vitroMuVSELcell
differentiation into multiple
germline tissues. (A) In primary
culture, MuVSEL cells were
freshly isolated from the bone
marrowofGFP-labeledanimals
and cocultured on mitomycin-
C-treated C2C12 cells for 2
weeks. Cells were placed in
specific differentiation media
conditions and were evaluated
for expression for (B) osteo-
blastic [osteocalcin (OC) and
Runx2], (C) endothelium
(CD31, Factor VIII), (D) neural
[nestin and neurofilament 200
(NF-200)]; yellow arrows indi-
cate neuron extensions, and (E)
insulin-producing endodermal
(insulin and C-peptide)-specific
markers. In each case, colocali-
zation of the specific antibody
(OC, Runx2, CD31, Factor
VIII, nestin, neruofilament 20
each stained red) with GFP
(stained green) was employed
(merged staining appears yel-
low). Red and green inserts
show each single color at 22%
size of the merged images. The
C2C12 cells did not express
GFP, and therefore in combi-
nation with any of the afore-
mentioned specific markers
represent internal negative con-
trols. (Note a few non-GFP ex-
pressing cells did stain for Runx
2 (labeled ‘‘A’’) likely derived
fromC2C12 cells).Large panel
immunohistochemistry images
presented at 40· , scale bar=
100mm.GFP,greenfluorescent
protein; MuVSEL, murine very
small embryonic like. Color
images available online atwww
.liebertpub.com/scd
Table 3. HuVSEL Gene Expression
VESL cells CD34 +
OCT-4 10.1 – 2.35a 1
SOX2 0.31 – 0.17a 1
Bmi1 59.7 – 21.9a 1
MYC 0.51 – 0.30a 1
KLF4 0.71 – 0.42 1
RUNX2 0 1
Osteocalcin 0 1
HuVSEL cells were isolated by apheresis from peripheral blood
following 3 days of granulocyte colony-stimulating factor mobiliza-
tion. HuVSEL cell gene expression was evaluated by real-time PCR
following reverse transcriptase and normalized to GAPDH expres-
sion. These values were compared to gene expression of mobilized
peripheral blood CD45+CD34+ cells isolated from the same subject,
which was set to 1.
ap < 0.05.
HuVSEL, human very small embryonic like.
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(Fig. 2A, lower left). For mesoderm differentiation, the
cocultures were examined for change in the expression of
chondrocyte-specific protein SOX9. Ectoderm differentia-
tion was examined with the neural markers nestin or bIII-
tubulin. Significant expression of each of these markers was
observed in cocultures induced with a pancreatic, chondro-
genic, or neurogenic medium (Fig. 2A).
HuVSEL cells were also capable of differentiating into
cells that expressed osteocalcin, which is indicative of os-
teoblastic differentiation (mesoderm) (Fig. 2B). The cells
also differentiated into cells that could express nestin in
conjunction with the characteristic morphology of neural
cells (ectoderm) (Fig. 2C). In other cultures, HuVSEL cells
could be induced toward the endodermal pancreatic b-cell
lineage as demonstrated by positive staining for insulin
(Fig. 2D). In each case, the expression of osteocalcin, nestin,
and insulin colocalized with staining for human HLA (Fig.
2B, C, D).
Serial transplantation of GFP transgenic
MuVSEL cells
To test the ability of VSEL cells to undergo self-renewal,
serial transplants of GFP-labeled MuVSEL cells were
FIG. 2. In vitro HuVSEL
cell differentiation into multi-
ple germline tissues. (A) In
primaryculture,HuVSELcells
were freshly isolated from pe-
ripheral blood and cocultured
on mitomycin-C-treated
C2C12 cells for 2 weeks. Ex-
pression of human GAPDH by
QRT-PCR was over 400-fold
higher in cocultures containing
HuVSEL cells compared with
cultures of C2C12 cells alone
(lower left panel). After 2




with baseline and normalized
to GAPDH were evaluated by
QRT-PCR for early neural/
pancreatic (PAX6), chondro-
genic (SOX9), and early
neurogenic (nestin and or bIII-
tubulin) markers. Cells were
also evaluated by immunoflu-
orescence microscopy for ex-
pression of (B) osteoblastic
(osteocalcin), (C) early neural
(nestin, yellow arrows indicate
neuron extensions), and (D)
insulin-producing endodermal
(insulin)-specific markers. In
each case, colocalization with
human HLA staining was as-
sessed.TheC2C12cellsdidnot
stain for any of the aforemen-
tioned markers. Negative con-
trol (Neg. Control) indicates
VSEL cells plated on C2C12
without specific tissue induc-
tion. Inserts show each single
color at 22%size of themerged
images. Large panel immuno-
histochemistry images pre-
sented at 40· , scale bar=
100mm.HuVSEL,humanvery
small embryonic like; PAX6,
paired box gene 6; QRT-PCR,
real time reverse transcriptase
polymerase chain reaction.
Color images available online
at www.liebertpub.com/scd
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injected into the tibias of locally irradiated mice (Fig. 3A).
After 3 months, the tibias were prepared for histology or
prepared for FACS analysis to identify GFP-labeled
MuVSEL cells. By FACS, *60% of the VSEL cells main-
tained their phenotype after the first round of transplants (Fig.
3B and Supplementary Fig. S4). Histology performed on the
tibias of passage 1 transplanted animals demonstrated the
characteristic morphology and histological locations of GFP-
expressing osteoblasts (Runx2), endothelial cells (CD31),
early neurons (nestin), and adipocyte (PPAR-g) cells (Fig.
3C). Peripheral blood of passage 1 mice was examined for
cells expressing both the pan-hematopoietic marker CD45
FIG. 3. Serial transplantation ofVSELcells. (A)Serial transplant studieswere performed by injectingGFP-labeledVSELcells
into the tibias of locally irradiatedmice. Threemonths after each transplant,micewere sacrificed and the presence ofGFP-derived
VSELcells andmature cellular lineageswas evaluated byFACSand immunofluorescencemicroscopyof serially sectioned tibias.
FACS (B) indicated that *60% of the number of GFP+ VSEL cells (small Lin-Sca-1+CD45- cells) transplanted could be
recovered after the first serial transplant from the injected tibia (Passage 1), but no GFP+ Lin-Sca-1+CD45- cells could be
recovered after subsequent transplants (Passage 2 and Passage 3). Second and third serial transplant data (mice were transplanted
with small GFP+ CD45- Sca-1- cells) indicated that although GFP+ VSEL cells could not be isolated, abundant GFP+ cells
could be identified by FACS remained at the site of injection. (C) Characteristic morphology and histologic locations of GFP-
expressing osteoblasts (Runx2), endothelial cells (CD31), neural stem or progenitor cells (nestin), and adipocytes (PPAR-g) were
observed in the P1mice suggesting thatmany of the donorMuVSEL cells had differentiated. Note: the brightness nestin-negative
control insert panelwas increased by 30% for visibility. Inserts show each single color at 22% size of themerged images.Arrows
indicate dual staining cells. Large panel immunohistochemistry images presented at 40· , scale bar= 100mm. FACS, fluores-
cence activated cell sorting. Color images available online at www.liebertpub.com/scd
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and GFP. In some cases, extremely low levels of CD45 +
cells in the peripheral blood of the transplanted animals
also were GFP + suggesting that the transplanted VSEL
cells may have undergone differentiation into hematopoi-
etic lineages (not shown). No GFP-labeled CD45 + cells
were identified in the blood of sham-transplanted animals
(not shown). At the completion of the second transplants,
no VSEL (small Lin -Sca-1 +CD45 - ) cells were isolated,
and therefore, only GFP-expressing CD45 - cells were
subsequently transplanted. As in the second round of
transplants, abundant GFP-expressing cells were observed
(not shown), but no VSEL cells were recovered (Fig. 3B).
Together, these data suggest that VSEL cells, under the
conditions of our assay, have a limited capacity for self-
renewal.
In vivo differentiation of HuVSEL cells
in a mouse bony defect model
To evaluate the possibility that HuVSEL cells are able
to generate osseous tissues in vivo, HuVSEL cells were
implanted into calvarial defects in SCID mice (CB17-
Prkdcscid/LCrlcoCrl), and microcomputed tomography and
histological studies were performed. Implantation of 2,000
HuVSEL cells produced robust mineralized tissue by 3
months. Significantly, woven bone was identified within the
calvarial defects (Fig. 4A), as well as when the cells were
implanted subcutaneously (not shown), compared with an-
imals implanted with collagen scaffolds alone (Fig. 4A).
Significantly more bone mineral content was observed in the
calvarial defects of VSEL-treated animals relative to cellu-
lar or scaffold controls (Fig. 4B). Woven bone formation
and a hematopoietic marrow were also observed within the
calvarial defects (Fig. 4C). Interestingly, when the HuVSEL
cells were implanted in subcutaneous spaces, significant
mineralized tissue was also formed demonstrating that the
transplanted cells could generate bone, or induce new bone
formation, independent of being placed in a bony site (Fig.
4A, B). Antibodies to human HLA demonstrated that the
newly generated tissues were of human origin (Fig. 4D).
Human-specific osteocalcin and RUNX2 staining along the
bone margins were observed indicative of osteoblast dif-
ferentiation (Fig. 4E).
A histologic examination of the calvarial defects isolated
areas of cells surrounded by matrices reminiscent of carti-
lage was observed. Staining of tissue for collagen type II,
which is specifically produced by chondrocytes, colocalized
with human-specific HLA staining (Fig. 4F). Robust stain-
ing of cells surrounding the lumens of vascular structures
was detected with antibody to human CD31, indicating
endothelial cells of human origin (Fig. 4F). Staining for
nestin identified cells with long processes between cell
bodies, suggesting early neuronal commitment (Fig. 4F).
Human-specific antibody to PPAR-g identified adipocytes
present within the calvarial defects (Fig. 4F). In each case,
no human-specific staining was present in the calvarial de-
fects of cellular or scaffold control treated animals (Fig. 4F).
Since HLA staining was seen in the bone marrow (Fig. 4D),
we explored whether HuVSEL cells, which had undergone
differentiation to the hematopoietic lineage peripheral blood
of HuVSEL cell transplanted animals, were examined by
FACS; however, the level of cells expressing human CD45
was at or below the level of detection (data not presented).
Together these data suggest that HuVSEL and MuVSEL
cells have the capacity to generate multiple tissue lineages
within an osseous wound, indicating VSEL cells function as
multipotent cells.
Tumor formation
Long-term safety is of prime concern when we consider
future studies in humans. The ability to generate teratomas
is often considered to be one of the hallmarks of pluri-
potency, yet a concern when potentially used in patients.
Teratomas or other tumors were not observed in any of the
CB17-Prkdcscid/LCrlcoCrl VSEL cell-implanted animals
(Table 4).
Since all our prior studies were performed in skeletally
mature animals, a subcutaneous ossicle model to implant
VSEL cells in rapidly developing or recently matured
bone was chosen. In the first group, GFP-bone ossicles
were established s.c. in SCID mice by implanting mu-
rine BMSCs infected with AdBMP7. At 1 month, the os-
sicles were exposed and VSEL cells isolated from GFP-
expressing mice were injected into the ossicles and fol-
lowed for 1 year (Fig. 5A, Top). In the second group,
VSEL cells were again isolated from GFP-expressing
mice and in this case, they were coinjected with BMSCs
infected with AdBMP7. As before, these animals were
followed for 1 year (Fig. 5A, Bottom). A final control
group was established using BMSCs infected with
AdBMP7, but these were not exposed to VSEL cells,
which expressed GFP. At the time of sacrifice, necropsy
identified no tumors at any site in any of the mice.
Abundant GFP staining was seen in the marrow and bone
structures of the recovered ossicles (Fig. 5B), suggesting
that many of the progeny of the VSEL cells remained
within the confines of the engineered tissue. Interestingly,
more GFP staining was observed in the ossicles in which
the VSEL cells had been coimplanted with the AdBMP-7
transduced BMSCs. Critically, no neoplastic tissues were
identified in the ossicles (Table 4).
Discussion
In the present report, we evaluated the ability of HuVSEL
and MuVSEL cells to give rise to mature cells in vitro and
in vivo and correlated this to gene expression and synthesis
of proteins from multiple germlines. We observed that both
HuVSEL and MuVSEL cells can be induced to express
markers that are consistent with the acquisition of osteo-
blastic (Runx2, osteocalcin), adipocytic (PPAR-g), and en-
dothelial phenotype (CD31, Factor VIII) cells that are
mesenchymal derivatives. Expression of insulin and C-
peptide was observed when HuVSEL and MuVSEL cells
were placed in a medium that induces mesodermal differ-
entiation. When induced toward neural differentiation,
nestin and neurofilament 200 expression was observed by
cells that were unipolar, bipolar, and multipolar with cell
processes extending away from a central cell body. When
HuVSEL cells were implanted into a cranial wound defect,
woven human bone was generated with marrow cavities.
Contained within the marrow spaces of the human bone,
human neural adipocytes, chondrocytes, and osteoblasts
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were identified. When MuVSEL cells isolated from GFP-
expressing mice were injected into the tibiae, colocalization of
either osteoblastic, neural, or blood vessel markers was ob-
servedwithGFP. Serial transplant studies usingMuVSELcells
demonstrated that the donor cells were able to differentiate into
cells that expressed RUNX2, CD31, nestin, or PPAR-g; how-
ever, no VSEL cells were recovered after the second round of
transplants nor did the cells generate teratoma-like structures
even after 1 year. Together the results of the primary and sec-
ondary transplants suggest that under the conditions of our
assays, donor VSEL cells have limited self-renewal capacity.
Together these studies suggest that VSEL cells are worthy of
further investigation for clinical regenerative therapies in os-
seous, neural, and connective tissue disorders.
FIG. 4. HuVSEL osseous repair of craniofacial defects. (A) Microcomputed tomography images of representative calvarial
defects. HuVSEL cells together with collagen carrier matrix were implanted into either calvarial defects (center panels) or
subcutaneously (right panels) at 2,000 HuVSEL cells/implant. Murine bone marrow stromal cells (BMSCs) transduced with
AdCMVBMP-7 were implanted as a positive control (left panel). Collagen carrier alone was used as a negative control (second
from left). When implanted both in calvarial defects and subcutaneously, 2,000 BMP-7 BMSCs and HuVSEL cells produced
mineralized tissue, whereas collagen carrier alone did not. (B) Tissue mineral content for each implant was averaged for
n= 5–7 animals. Controls and implanted cell numbers were the same as in A. Implants using HuVSEL cells or BMP-7 BMSCs
produced significantly more tissue mineral content than implants using collagen carrier alone (*P< 0.05). (C) Representative
sections of calvarial defects stained with H&E (top row) and Masson’s trichrome (bottom row, which stains both collagen and
bone blue). Histology is shown at 20· (inserts) and 40· magnification. Positive controls were implanted with murine BMSCs
expressing BMP-7 (not shown). Negative controls (left panels) were implanted with collagen carrier alone (eg, no VSEL cells).
Note the persistence of the collagen carrier matrix in the negative control group as well as the absence of an inflammatory
cell infiltrate. Implants with 2,000 HuVSEL cells demonstrated woven bone containing marrow spaces (arrows). Scale
bar= 100mm. (D) Immunostaining of implanted calvarial defects using a fluorescent antibody to human HLA. (E) Im-
munostaining for human-specific antibody to osteocalcin (OC) and Runx2 (both in red) merged with images of antinuclear
stain (DAPI). Top left panel shows negative controls (Neg. Control: implanted with collagen vehicle only, but no VSEL cells)
exhibiting no osteocalcin or Runx2 staining. In contrast, tissue sections of HuVSEL implants show significant osteocalcin and
Runx2 staining along the bone margin as well as in the marrow cavity. Arrows indicate positive cells. Inserts show each single
color at 22% size of the merged images. Large panel immunohistochemistry images presented at 40· , scale bar= 100mm.
Dashed white line outlines the bone margins. (F) H&E staining of tissue sections (top row) show morphologically charac-
teristic cartilage, endothelial, and adipose tissue within the calvarial defect. Immunostaining of defects implanted with
HuVSEL cells (bottom row) shows robust staining for collagen type-II colocalized with human HLA (left panel, identifying
chondrocytes) as well as staining surrounding the lumens of vascular structures detected with antibody to human CD31
(second from left). Human-specific antibody to PPAR-g (second from right) identifies adipocytes within the calvarial defects.
Staining for human nestin (right) identified cells with long processes between cell bodies, indicating early neuronal differ-
entiation. In each case, no human-specific staining was present in the calvarial defects of cellular or scaffold control treated
animals (center row). (Neg. Control: implanted with collagen vehicle only, but no VSEL cells) Histologic images presented at
40· , scale bar= 100mm. Arrows indicate positive staining. Color images available online at www.liebertpub.com/scd
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To our knowledge, this report represents the first dem-
onstration that HuVSEL cells are able to differentiate into
multiple cell lineages in vivo and in vitro [6,18,19]. Thus,
our data represent an advancement for the field. Previously,
we demonstrated that HuVSEL and MuVSEL cells are able
to generate osteoblasts in vitro following implantation into
osseous wound sites or when implanted in s.c. site. It is true
that our studies cannot exclude the possibility that a small
fraction of hematopoietic cells were carried over in our
HuVSEL cell preparations, even with CD45 exclusion. It is
possible therefore that some of the activities may have been
due to a low level of contaminating cells. However, since
the level of engraftment of human CD45 was less than 1%,
this possibility appears very unlikely (data not presented),
particularly since the animals were not specifically prepared
for engraftment by radiation therapy.
It is also true that our studies were not performed with
single cell engraftment nor did we perform nuclear tracking
FIG. 4. (Continued).
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studies. Numerous reports have demonstrated that cell fu-
sion may play a significant role in the transdifferentiation of
cells [20–23]. Therefore, we cannot formally exclude the
possibility of cellular fusion. However, if fusion played a
significant role in the induction of the mature phenotypes
that we observed in culture, we would have seen multiple
cells with nuclei that were closer in size to the larger C2C12
nuclei. Therefore, one of the criteria for demonstrating
differentiation in our in vitro cultures into any of the line-
ages we observed was a cell with a smaller nucleus.
Moreover, while C2C12 can differentiate into osteoblastic
and mesenchymal lineages [24–27], the ability of these cells
to activate an endodermal (pancreatic b-cell) or neural
(nestin or neurofilament 200) phenotype is unlikely. In ad-
dition, it is unlikely that a fused cell in vivo would continue
to express human HLA to the levels we observed. Never-
theless, formal proof that cell fusion did or did not play a
role in our studies will require further investigation.
Recently, several groups have reported that they have
been unable to isolate VSEL cells and suggest that there are
insufficient animal data to warrant human clinical trials [28–
30]. There is no doubt that isolation of VSEL cells and their
cultivation is a difficult endeavor. Given that several inde-
pendent groups can isolate VSEL cells and have confirmed
the in vitro differentiation data [18,31–33], we believe that
the reasons for the differences in experimental results are of
a technical nature. These differences that are outlined in
great detail in a recent publication are most likely due to
inadequate isolation procedures [34–36]. Nevertheless,
some of the critiques of the VSEL cell field are valid; more
systematic studies are needed.
At no point did we observe any evidence for teratoma
formation in any of the experimental animals, either at the
site of injection or at a distant location. Teratoma formation
has been used as part of the criteria that have been estab-
lished to define pluripotency of ES cells. In fact, VSEL cells
fail to contribute to the development of chimeric embryos
when injected into blastocysts. We speculate that part of the
reason for the failure of VSEL cells to fulfill all of the
functional criteria used to define pluripotency may be that
the cells have undergone genomic imprinting to limit the
ability of the cells to undergo unregulated growth. Yet,
MuVSEL and HuVSEL cells express numerous markers
associated with a stem cell phenotype, including Oct4 and
Bmi1 [37]. Moreover, in vivo we observed the development
of tissues derived from HuVSEL cells, including bone,
cartilage, blood vessels, fat, and nerve-like structures as well
as the formation of a marrow cavity complete with CD45 +
expressing cells. Thus, HuVSEL cells fulfill many of the
criteria of multipotency in vivo by generating tissues con-
sistent with derivatives from two out of the three germlines
within a cranial wound.
These studies did not demonstrate unlimited capacity of
MuVSEL cells to self-renew using serial transplantation
methodologies. There are several possible reasons for these
observations. (i) In the first round of serial transplantation
studies, we implanted equal numbers of GFP-labeled
MuVSEL cells into the tibia of sublethally irradiated and
nonirradiated mice (not shown). As recovery of the GFP-
labeled VSEL cells was lower than expected, but was
slightly higher for the irradiated group, we continued the
studies focusing on the irradiated group exclusively. In
retrospect, this was likely a mistake as the wounding process
itself likely placed selective pressure on the VSEL cells to
undergo differentiation rather than self-renewal. (ii) A sec-
ond possibility is that, the VSEL cells migrated away from
the tibia. Previously, it was demonstrated that human cell or
DNA is present in the peripheral blood of animals implanted
with HuVSEL cells [15], and that VSEL cells can contribute
to hematopoietic reconstitution [38]. Thus, it is possible that
the transplanted VSEL cells migrated away from the site of
implantation although a careful and more extensive survey
of the host tissues would be required. (iii) It is also possible
that the results we observed during the recovery of VSEL
FIG. 4. (Continued).
698 HAVENS ET AL.
cells in the serial transplantations were due almost exclu-
sively to the aging process. The VSEL cells used in this
study were derived from mice that were 6–8 weeks old.
Thus, after two rounds of transplantation, the VSEL cells
could have been as old as 8 months. Previous studies have
demonstrated that VSEL cell loss occurs with increasing age
[39]. Moreover, the serial transplant studies were performed
in immunocompetent mice. We are now aware that GFP is
immunogenic, and perhaps, this is, in part, why it was not
possible to recover VSEL cells after the second transplan-
tation [40]. These studies will be repeated in immunodefi-
cient animals. It is also quite relevant to consider that
context matters considerably in the systems used to identify
stem cell activity, and therefore, the door should remain
open before VSEL cells are defined as stem or progenitor
cells. [41–43]. In fact, there are examples in the adult stem
cell field where serial transplantation has not successfully
been used to define stem cells [44].
In summary, to treat the complex and multitissue regen-
erative challenges inherent in tissue and organ repair, the
identification of therapies or cells with inherent plasticity
would be most desirable. VSEL cells represent an endoge-
nous cellular population that is readily mobilized in re-
sponse to wounds and can be isolated from a number of
FIG. 5. Long-term subcutaneous ossicle implantation ofMuVSEL cells. (A) Experimental Outline. Top:Murine BMSCswere
infectedwith an adenovirus designed to overexpressBMP7 (AdBMP7),whichwere then implanted s.c. into SCIDmice for up to 1
year. In some cases, the resulting ossicles were exposed and injected directly with MuVSEL cells isolated from GFP transgenic
mice. Bottom: BMSCs infected with AdBMP7 were coinjected with MuVSEL cells isolated from GFP-expressing mice. At 12
months, all ossicles were recovered, decalcified, and stained with an antibody to GFP. (B) Staining for GFP expression in
decalcifiedossicles recoveredBMSC/AdBMP7-implanted animals (left), fromBMSC/AdBMP7-implantedanimals,which after 1
monthwere exposed and injectedwithGFP-VSELcells (middle), or ossicles establishedwithBMSC/AdBMP7 that also contained
GFP-VSEL cells at the time of implantation (right). Staining used anti-GFP HRP-AEC (red), counterstained with H&E (light
blue). Little to no specific immunostaining for GFP was observed when the ossicles were not exposed to GFP-VSEL cells (left).
Abundant staining of the bone marrow and bone structures were observed when the ossicles had been injected with GFP-VSEL
cells. Positive staining for GFP appears in red. Scale bar= 100mm. Color images available online at www.liebertpub.com/scd
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tissue sources. In the present study, we demonstrate that
both HuVSEL and MuVSEL cells are capable of multi-
lineage cellular differentiation in vitro. In vivo, multiple
donor-derived tissue lineages, including endothelial cells,
nerves, adipocytes, chondrocytes, and hematopoietic cells,
were observed to be derived from HuVSEL cells, in addition
to our previous demonstration of osteoblasts. These obser-
vations suggest that VSEL cells are safe and may be po-
tentially useful therapeutic tools for tissue regeneration.
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